Skip to main content Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: NGNE

Neurogene Inc.

Healthcare | Biotechnology
$21.61 +0.00 (+3.35%) as of 2026-07-14 21:19 UTC
Market Cap$340M
Volume76.1K
EPS (TTM)$-4.24

Neurogene Inc. (NASDAQ: NGNE) is a $340M biotechnology company trading at $21.61 (+3.3% today). Figures from SEC EDGAR and market feeds; updated 2026-07-14 21:19 UTC.

52-Week Range
Low $21.61High $21.61

What Neurogene Inc. does

Neurogenesis Therapeutics is a clinical-stage biotechnology company developing genetic medicines for rare neurological diseases that cannot be effectively treated with conventional gene therapy. The company uses proprietary transgene regulation technology called EXACT, which employs microRNA-based genetic circuits to deliver therapeutic levels of treatment to affected brain regions.

Summarized from Neurogene Inc.’s SEC filings · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.
Key facts
Quote
Price$21.61
Change (1D)+0.00 (+3.35%)
Market cap$340M
Volume76.1K shares
52-week range$21.61 – $21.61
Valuation
EPS (TTM)$-4.24
Price/book1.28×
Returns
52-week return+0.0%
Price Chart
52-Week Range
Low $21.61High $21.61
Interactive chart available in terminalLive price charts with full OHLCV data, volume overlay, and technical indicators.
Open NGNE in Platform →
SEC Filings SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-07-07
  • 2026-07-07Cvijic Christine MikailPresident and CFOSELL-600$21.6K
  • 2026-07-07Cvijic Christine MikailPresident and CFOSELL-4,200$151.8K
  • 2026-07-02Cvijic Christine MikailPresident and CFOSELL-2,531$87.5K
Sign in to see all transactions →
Top Institutional Holders (latest 13F)
Source: SEC EDGAR · As of 2026-Q1
  • SAMSARA BIOCAPITAL, LLC1,717,127$34.62M0.0%
  • Redmile Group, LLC1,459,599$29.43M0.0%
  • Casdin Capital, LLC1,420,361$28.63M+9.7%
View QoQ ownership changes →
Company news View all →
No qualifying company news in the archive. Full tape in the platform →
Questions this page answers

What does Neurogene Inc. do?

Neurogenesis Therapeutics is a clinical-stage biotechnology company developing genetic medicines for rare neurological diseases that cannot be effectively treated with conventional gene therapy.

What is NGNE's valuation?

NGNE trades at $21.61, as of 2026-07-14.

When did NGNE last file with the SEC?

Neurogene Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-02. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-07-14 21:19 UTC. This page is also available as JSON at /api/data?ticker=NGNE and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for NGNE and 3,500+ tickers.

Create a free account — keep NGNE
For your agent
GET /api/data?ticker=NGNE

This page as JSON via rel="alternate" · REST API docs · MCP server (51 tools) · llms.txt